Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare…
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains…
Read More...
Read More...